2020-10-20
1: Malih S, Najafi R. AdipoRon: a possible drug for colorectal cancer prevention? Tumour Biol. 2015 Aug 18. [Epub ahead of print] PubMed PMID: 26282004. 
  
2: Zhang Y, Zhao J, Li R, Lau WB, Yuan YX, Liang B, Li R, Gao EH, Koch WJ, Ma XL, Wang YJ. AdipoRon, the first orally active adiponectin receptor activator, attenuates postischemic myocardial apoptosis through both AMPK-mediated and AMPK-independent signalings. Am J Physiol Endocrinol Metab. 2015 Aug 1;309(3):E275-82. doi: 10.1152/ajpendo.00577.2014. Epub 2015 Jun 2. PubMed PMID:  26037251; PubMed Central PMCID: PMC4525114. 
  
3: Dib J, Schlörer N, Schänzer W, Thevis M. Studies on the collision-induced dissociation of adipoR agonists after electrospray ionization and their implementation in sports drug testing. J Mass Spectrom. 2015 Feb;50(2):407-17. doi: 10.1002/jms.3545. PubMed PMID: 25800023. 
  
4: Lee S, Kwak HB. Role of adiponectin in metabolic and cardiovascular disease. J Exerc Rehabil. 2014 Apr 30;10(2):54-9. doi: 10.12965/jer.140100. eCollection 2014 Apr. Review. PubMed PMID: 24877038; PubMed Central PMCID: PMC4025550. 
  
5: Holland WL, Scherer PE. Cell Biology. Ronning after the adiponectin receptors. Science. 2013 Dec 20;342(6165):1460-1. doi: 10.1126/science.1249077. PubMed PMID: 24357309; PubMed Central PMCID: PMC4084614. 
  
6: Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi  M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T,  Tanaka A, Yokoyama S, Kadowaki T. A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature. 2013 Nov 28;503(7477):493-9. doi: 10.1038/nature12656. Epub 2013 Oct 30. PubMed PMID: 24172895.